Highlights Karyopharm Therapeutics Inc.

Equities

KPTI

US48576U1060

Real-time Estimate Cboe BZX Other stock markets 10:17:45 2024-05-20 am EDT			5-day change	1st Jan Change
1.175 ^USD	+2.17%		+4.46%	+35.26%

May. 08	Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Reports Q1 Revenue $33.1M, vs. Street Est of $34.5M	MT
May. 08	Transcript : Karyopharm Therapeutics Inc., Q1 2024 Earnings Call, May 08, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Reports Q1 Revenue $33.1M, vs. Street Est of $34.5M	May. 08	MT
Karyopharm Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full Year of 2024	May. 08	CI
Karyopharm Therapeutics Inc. Announces Presentations in Endometrial Cancer and Myelofibrosis At the 2024 American Society of Clinical Oncology Annual Meeting	Apr. 24	CI
Karyopharm Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Posts Q4 Revenue $33.7M, vs. Street Est of $33.6M	Feb. 29	MT
Karyopharm Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2024	Feb. 29	CI
North American Morning Briefing : Fed's Preferred -2-	Feb. 29	DJ
North American Morning Briefing : Stock Futures -2-	Feb. 21	DJ
Karyopharm Therapeutics Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year 2023	Jan. 08	CI
Karyopharm Therapeutics Inc. Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi-Naive Myelofib) Patients	Dec. 10	CI
Karyopharm Therapeutics Inc. Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition	Nov. 02	CI
Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Posts Q3 Revenue $36M, vs. Street Est of $37.4M	Nov. 02	MT
Karyopharm Therapeutics Inc. Reiterates Revenue Guidance for the Full Year 2023	Nov. 02	CI
Karyopharm Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Karyopharm Therapeutics Inc. Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD?? Agent CC-92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma	23-10-30	CI
Karyopharm Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Posts Q2 Revenue $37.6M, vs. Street Est of $35.7M	23-08-02	MT
Karyopharm Therapeutics Inc. Announces Earnings Guidance for the Year 2023	23-08-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Karyopharm Therapeutics Inc.

Equities

KPTI

US48576U1060

Highlights

Filters